These medications (including semaglutide, dulaglutide, and liraglutide) are typically considered when: Metformin and other oral medications have not achieved adequate glycaemic control The patient has a BMI 35 kg/m (or lower thresholds, typically by around 2.5 kg/m, for people of certain ethnic backgrounds including South Asian) Weight loss would benefit other obesity-related comorbidities Insulin therapy is being considered but would have significant occupational implications or weight gain is a concern Continuation criteria apply: for example, treatment should reduce HbA1c by at least 11 mmol/mol (1.0%) and weight by at least 3% at 6 months to be continued
Diabetes Res Clin Pract 73: 107-110, 2006
Ro is uniquely adept at collecting the right information, confirming each patients options, and giving them clear next steps having conducted tens of thousands of benefits checks this year
Ther Adv Endocrinol Metab
I have been a Certified Diabetes Educator since 1986 and in all those years cant recall a case of thyroid cancer from taking a GLP-1
I received my medication in 5 to my surprise this medication really works